Golden Meditech Holdings Limited (the “Company” or “Golden Meditech”; 801.HK), together with its subsidiaries (collectively referred to as the “Group”), is a leading integrated medical devices and healthcare services player in China.

Golden Meditech is recognised as the first-mover in China’s healthcare industry with a proven track-record in identifying, grooming and establishing business operations with dominant positions in niche market segments within the industry, including medical devices, cord blood banking, hospital management and related healthcare services.

In the long run, the Group is committed to achieving long-term growth through the following strategies:

• Position ourselves as the “entrepreneur + operator + cornerstone investor”
• Focus on medical devices and healthcare services operations, addressing both    hospital and general public markets
• Invest in healthcare projects with huge market potential, limited competition, and great    investment returns
• Enhance shareholders’ value through successful listings of operations (e.g. Chin Cord Blood Corporation (CO.US), FunTalk China Holdings Limited (FTLK.US) )

As a leading integrated medical devices and healthcare services player in China with prominent presence in niche and lucrative markets, our seasoned management team has a proven track record for their execution capabilities

• First and largest blood-related devices manufacturer
• First foreign-owned company licensed to manage hospitals nationwide
• First medical insurance information management and BPO Service Provider in China

i. Medical Devices Segment

Primarily engaged in the development, manufacture, sales and distribution of blood-related medical devices, the Group has been focusingon the development of blood recovery, purification, treatment, and preservation technologies.  Our key products include the Autologous Blood Recovery System (the “ABRS”), the first of its kind to obtain the approval of the State Food and Drug Administration (“SFDA”), the Plasma Exchange System and the Accelerated Thermostatic Infusion Pump. 

ii. Healthcare Services Segment

Focusing on hospital management and related services, the Group is the first and only foreign company with a nationwide hospital management license in China. We currently manage two largest haematology specialist hospitals in China.

We are the first and leading provider of medical insurance information management and back-office administration business process outsourcing (“BPO”) services in China, assisting both foreign and domestic medical insurance companies in China. 

The Group is also a substantial shareholder of China Cord Blood Corporation (CO.US; “CCBC”), the first and largest umbilical cord blood bank in China with exclusive licenses in Beijing and Guangdong, and an investment in the exclusive operator in Shandong.

CCBC is also the single largest shareholder of Cordlife Ltd. (CBB.AX), Southeast Asia’s largest cord blood bank operator.  Over the years, we have successfully established dominant positions in each market via our proven strategy to position ourselves as the “entrepreneur + operator + cornerstone investor,” thanks to our strengths in innovation and market expertise, and the ability in capturing emerging market opportunities. This has enabled us to unleash the intrinsic value of each business unit, releasing the Group’s resources to focus on operation, speeding up the uptake of market share and effectively accelerating business growth.